



- If you are viewing this course as a recorded course after the live webinar, you can use the scroll bar at the bottom of the player window to pause and navigate the course.
- This handout is for reference only. It may not include content identical to the PowerPoint. Any links included in the handout are current at the time of the live webinar, but are subject to change and may not be current at a later date.



© 2017 continued.com, LLC. No part of the materials available through the continued.com site may be copied, photocopied, reproduced, translated or reduced to any electronic medium or machine-readable form, in whole or in part, without prior written consent of continued.com, LLC. Any other reproduction in any form without the permission of continued.com, LLC is prohibited. All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of continued.com, LLC. Users must not access or use for any commercial purposes any part of the site or any services or materials available through the site.

Dysphagia in Neurodegenerative Disease

Focus on Amyotrophic Lateral Sclerosis & Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

- "A" means no or negative.
- "Myo" refers to muscle
- "Trophic" means nourishment
 - So, "Amyotrophic" = "No muscle nourishment"
 - When a muscle has no nourishment, it "atrophies."
- "Lateral" identifies the areas in a person's spinal cord where portions of the nerve cells that nourish the muscles are located.
 - As this area degenerates it leads to scarring or hardening ("sclerosis") in the region.

ALS

- ALS involves both upper and lower motor neurons
- Presents as an idiopathic, progressive degeneration of anterior horn cells and their associated neurons resulting in progressive muscle weakness, atrophy, and fasciculations.

ALS

- There is degeneration of:
 - The lateral corticospinal tracts
 - Anterior horn cells
 - Anterior roots and peripheral nerves
 - Nuclei of cranial nerves V, VII, IX, and XII
 - Corticobulbar tracts

ALS

- Prevalence of ALS in the United States is estimated at 25,000-30,000 cases
- The incidence of ALS is two per 100,000 people.
- Approximately 5,600 people in the U.S. are diagnosed with ALS each year.

ALS

- In the United States, 90–95% of ALS cases are sporadic.
 - Military personnel are more likely to develop ALS than the general population.
- 5% are familial ALS
 - FALS is linked to a genetic defect on chromosome 9.

ALS

- Causes
 - Not completely understood.
 - Researchers and physicians suspect viruses, neurotoxins, heavy metals, DNA defects (especially in familial ALS), immune system abnormalities, and enzyme abnormalities.

ALS

- The clinical picture in all stages of ALS can vary and depends on the areas of the nervous system involved in each patient.
- Overall, the disease tends to be insidious and progressive with asymmetric weakness and atrophy.

ALS

- Three types:
 - Bulbar
 - Most rapidly progressive form
 - Involves muscles innervated by cranial nerves involved in speech and swallowing
 - Spinal
 - Progresses more slowly
 - Involves upper and lower extremities controlled by spinal nerves
 - Mixed
 - Includes symptoms of both bulbar and spinal forms

ALS Diagnosis

- Nerve conduction velocity (NCV) and electromyography (EMG) help diagnose nerve and muscle disorders.
 - NCV is administered before EMG and measures the speed at which nerves transmit electrical signals.

ALS Treatment

- There is no cure.
- Riluzole (Rilutek®) is one of the few drugs effective against ALS and may prevent progression and prolong life for a few months or so.
- Treatment focuses on relieving symptoms and maintaining an optimal quality of life.

ALS: Prognosis

- ALS is a terminal illness.
 - 50% of patients die within 3 years of diagnosis
 - 20% live 5 years
 - 10% live 10 years

ALS Severity Scale

(Hillel et al., 1989)

- Used to rate function in four areas:
 - Speech
 - Swallowing
 - Lower Extremities
 - Upper Extremities

ALS Severity Scale

(Hillel et al., 1989)

- Swallowing subscale:
 - 10 Points
 - 9-10 Normal Eating Habits
 - Normal-to-nominal abnormality
 - 7-8 Early Eating Problems
 - 8: Isolated choking episodes; regular diet
 - 7: Prolonged meal times or smaller bite size
 - 5-6 Dietary Consistency Changes
 - 6: Soft diet
 - 5: Liquefied diet
 - 3-4 Needs Tube Feeding
 - 4: Supplemental tube feedings
 - 3: Tube feeding with occasional po nutrition
 - 1-2 NPO
 - 2: Secretions managed with suction or medication or both
 - 1: Aspiration of secretions

Dysphagia in ALS

- Onset is going to vary depending upon type of ALS.
 - May be initial symptom in individuals with bulbar onset ALS.

Dysphagia in ALS

- Dysphagia management may be affected by co-occurrence of mild cognitive impairment or fronto-temporal dementia.

Dysphagia in ALS

- Speech-language pathologists often work as part of a multi-disciplinary team that may include:
 - Neurologists
 - Respiratory Therapists
 - Pulmonologists
 - Rehab Specialists: PT, OT, KT
 - Social Workers
 - Mental Health

Dysphagia in ALS

- Oral Phase Dysphagia
 - Lingual weakness is often more pronounced than jaw or lip weakness (Weikamp et al., 2012)
 - Tongue strength has been found to be a prognostic indicator of survival in ALS.

Dysphagia in ALS

- Pharyngeal phase
 - Reduced laryngeal elevation
 - Reductions in pharyngeal constrictor movement
- Cervical esophageal
 - UES involvement

Dysphagia in ALS

- Initial complaints may be of occasional choking with liquids or solids.
- Individuals may complain of difficulty chewing hard, crunchy foods.
- Our role:
 - Counseling regarding safer food choices.
 - Instrumental swallow assessment if indicated.

Dysphagia in ALS

- Depending upon individual's readiness, may discuss need to consider feeding tube placement.
 - Timing of tube placement is important
 - Weight loss of 10% or more from premorbid weight (Anderson et al., 2005)
 - Vital capacity should be >50% of predicted value (Miller et al., 2009)
 - Encourage continued p.o. intake

Dysphagia in ALS

- Individuals may complain of difficulty taking liquids from a cup
 - Many choose to use a straw instead.
 - May recommend metered dose type cup to control bolus flow and size.

Dysphagia in ALS

- Sialorrhea may be a complaint
 - Botox appears to be safe and effective.

Stokholm et al., 2013

Dysphagia in ALS

- Recommend regular follow-up with individuals
 - Our role is to continue to make recommendations for diet modifications
 - May suggest liquefying foods or adding gravies/sauces to foods
 - Suggest altering diet consistency
 - Suggest smaller meals distributed throughout the day.

Dysphagia in ALS

- Exercise-based programs
 - Very little empirical evidence that strength training improves or maintains function in the limbs
 - Some evidence that respiratory training may help maintain respiratory function
 - To date, there is no empirical evidence to support exercise-based program for treatment of dysphagia in individuals with ALS.

Parkinson's Disease

- One million people in the U.S. have Parkinson's Disease
- Approximately 60,000 new cases of Parkinson's disease are diagnosed in the U.S. each year.
- The incidence of Parkinson's disease increases with age, but 4% of cases occur before the age of 50.

• Statistics from Parkinson's Disease Foundation

Parkinson's Disease

- Results from damage to the substantia nigra, which produces dopamine.
- Reduction in dopamine results in an imbalance in neurotransmitters
 - Too much acetylcholine; too little dopamine
- Characteristics include:
 - Rigidity -Tremor
 - Bradykinesia -Disturbed Postural Reflexes

Parkinson's Disease

- Difficulty can occur in any phase of swallowing
 - Oral
 - Pharyngeal
 - Esophageal

Parkinson's Disease

- Oral Phase
 - Difficulties with this phase usually occur first.
 - May include:
 - Difficulty chewing
 - Tongue pumping behavior
 - Non-propulsive back and forth motion of the tongue
 - Anterior spillage of material
 - Drooling
 - Due to reduction in frequency of swallowing
 - Up to 55% of patients with Parkinson's report xerostomia

Tjaden, 2008

Parkinson' Disease

- Pharyngeal Phase:
 - Delayed initiation of the pharyngeal swallow
 - Decreased tongue base retraction
 - Decreased pharyngeal contraction
 - Decreased hyolaryngeal excursion
 - Decreased airway protection during the swallow

Parkinson's Disease

- Esophageal Phase:
 - Decreased UES opening
 - Decreased esophageal motility
 - Patients complain of feeling as if food gets stuck

Sung et al., 2010

Parkinson's Disease

- Co-occurrence of dementia can affect swallow safety
 - Impulsivity
 - Lack of awareness of swallowing difficulty

Parkinson's Disease

- Dysphagia Treatment
 - Lee Silverman Voice Treatment
 - Diet Modification
 - Rehabilitative Exercises
 - EMST
 - Lingual strengthening
 - Compensatory Strategies

Parkinson's Disease

- Sialorrhea Treatment
 - Dopaminergic drugs may have some benefit
 - Botox injections to the salivary glands appear to be most effective.

Srivanitchapoom et al., 2014

Conclusions

- Treatment of dysphagia in patients with neurodegenerative disease requires a unique approach and depends upon the neurological underpinnings of the disease.
- Clinicians must have a thorough understanding of the disease causing the dysphagia in order to formulate an appropriate treatment plan.
